Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""TUMOR necrosis factor"" wg kryterium: Temat


Tytuł :
Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients.
Autorzy :
Greener T; Digestive Disease Institute, Sha'are Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Boland K; Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital IBD Centre, Ontario.; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada.
Milgrom R; Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital IBD Centre, Ontario.; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada.
Ben-Bassat O; Department of Gastroenterology, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Steinhart AH; Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital IBD Centre, Ontario.; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada.
Silverberg MS; Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital IBD Centre, Ontario.; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada.
Narula N; Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2021 Oct 01; Vol. 33 (10), pp. 1274-1279.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Crohn Disease*/diagnosis
Crohn Disease*/drug therapy
Tumor Necrosis Factor Inhibitors*
Adalimumab/adverse effects ; Humans ; Infliximab ; Retrospective Studies ; Treatment Outcome ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Tytuł :
Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease.
Autorzy :
Hradsky O; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic. .
Kazeka D; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Copova I; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Lerchova T; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Mitrova K; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Pospisilova K; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Sulovcova M; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Zarubova K; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Bronsky J; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Prague, Czech Republic.
Pokaż więcej
Źródło :
European journal of pediatrics [Eur J Pediatr] 2021 Sep; Vol. 180 (9), pp. 3001-3008. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji :
Journal Article
MeSH Terms :
Crohn Disease*/complications
Crohn Disease*/drug therapy
Tumor Necrosis Factor Inhibitors*
Child ; Humans ; Infliximab/adverse effects ; Retrospective Studies ; Risk Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Tytuł :
Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
Autorzy :
Blesl A; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Högenauer C; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.; Biotechmed, Graz, Austria.
Borenich A; Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
Berghold A; Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
Wenzl H; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Petritsch W; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Sep; Vol. 54 (5), pp. 720-721.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Inflammatory Bowel Diseases*
Tumor Necrosis Factor Inhibitors*
Humans ; Treatment Outcome ; Tumor Necrosis Factor-alpha
Opinia redakcyjna
Tytuł :
A wake-like state in vitro induced by transmembrane TNF/soluble TNF receptor reverse signaling.
Autorzy :
Dykstra-Aiello C; Department of Integrative Physiology and Neuroscience, Washington State University-Spokane, WA, United States. Electronic address: .
Koh KMS; Department of Integrative Physiology and Neuroscience, Washington State University-Spokane, WA, United States.
Nguyen J; Department of Integrative Physiology and Neuroscience, Washington State University-Spokane, WA, United States.
Xue M; Department of Electrical Engineering, Washington State University-Pullman, WA, United States.
Roy S; Department of Electrical Engineering, Washington State University-Pullman, WA, United States.
Krueger JM; Department of Integrative Physiology and Neuroscience, Washington State University-Spokane, WA, United States.
Pokaż więcej
Źródło :
Brain, behavior, and immunity [Brain Behav Immun] 2021 May; Vol. 94, pp. 245-258. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Receptors, Tumor Necrosis Factor, Type II*
Tumor Necrosis Factor-alpha*
Animals ; Female ; Male ; Mice ; Neuroglia ; Neurons ; Receptors, Tumor Necrosis Factor, Type I ; Signal Transduction
Czasopismo naukowe
Tytuł :
Anti-TNF-α-induced lupus syndrome : Two case reports and review of current literature.
Autorzy :
Sieiro Santos C; Rheumatology Department, Complejo Asistencial Universitario de León, Calle Altos de nava, s/n, 24001, León, Spain. .
Álvarez Castro C; Rheumatology Department, Complejo Asistencial Universitario de León, Calle Altos de nava, s/n, 24001, León, Spain.
Moriano Morales C
Díez Álvarez E
Pokaż więcej
Transliterated Title :
Anti-TNF-α-induziertes Lupussyndrom : Übersicht über die aktuelle Literatur und 2 Kasuistiken.
Źródło :
Zeitschrift fur Rheumatologie [Z Rheumatol] 2021 Jun; Vol. 80 (5), pp. 481-486. Date of Electronic Publication: 2021 Mar 11.
Typ publikacji :
Case Reports; Journal Article; Review
MeSH Terms :
Antirheumatic Agents*/adverse effects
Tumor Necrosis Factor Inhibitors*
Adalimumab ; Antibodies, Monoclonal ; Etanercept/adverse effects ; Humans ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Tytuł :
Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?
Autorzy :
Pugliese D; CEMAD, IBD UNIT, Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.
Armuzzi A; CEMAD, IBD UNIT, Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.; Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jul; Vol. 54 (1), pp. 84-85.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Inflammatory Bowel Diseases*
Tumor Necrosis Factor Inhibitors*
Biological Therapy ; Humans ; Infliximab ; Tumor Necrosis Factor-alpha
Opinia redakcyjna
Tytuł :
Golimumab (anti-TNF monoclonal antibody): where we stand today.
Autorzy :
Melo AT; Rheumatology Department, Hospital De Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.; Rheumatology Research Unit, Instituto De Medicina Molecular João Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa, Lisbon, Portugal.
Campanilho-Marques R; Rheumatology Department, Hospital De Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.; Rheumatology Research Unit, Instituto De Medicina Molecular João Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa, Lisbon, Portugal.
Fonseca JE; Rheumatology Department, Hospital De Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.; Rheumatology Research Unit, Instituto De Medicina Molecular João Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa, Lisbon, Portugal.
Pokaż więcej
Źródło :
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Jun 03; Vol. 17 (6), pp. 1586-1598. Date of Electronic Publication: 2020 Dec 28.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Spondylitis, Ankylosing*
Tumor Necrosis Factor Inhibitors*
Antibodies, Monoclonal ; Humans ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Tytuł :
The association of preoperative TNF-alpha inhibitor use and reoperation rates in spinal fusion surgery.
Autorzy :
Gaudiani MA; Case Western Reserve University School of Medicine, 10900 Euclid Ave, Cleveland, OH 44106, USA.
Winkelman RD; Center for Spine Health, Cleveland Clinic, Desk S40, 9500 Euclid Ave, Cleveland, OH 44195, USA.
Ravishankar P; Case Western Reserve University School of Medicine, 10900 Euclid Ave, Cleveland, OH 44106, USA.
Rabah NM; Case Western Reserve University School of Medicine, 10900 Euclid Ave, Cleveland, OH 44106, USA.
Mroz TE; Center for Spine Health, Cleveland Clinic, Desk S40, 9500 Euclid Ave, Cleveland, OH 44195, USA. Electronic address: .
Coughlin DJ; Center for Spine Health, Cleveland Clinic, Desk S40, 9500 Euclid Ave, Cleveland, OH 44195, USA.
Pokaż więcej
Źródło :
The spine journal : official journal of the North American Spine Society [Spine J] 2021 Jun; Vol. 21 (6), pp. 972-979. Date of Electronic Publication: 2021 Feb 02.
Typ publikacji :
Journal Article
MeSH Terms :
Spinal Fusion*/adverse effects
Tumor Necrosis Factor-alpha*
Humans ; Postoperative Complications/chemically induced ; Postoperative Complications/epidemiology ; Postoperative Complications/surgery ; Reoperation ; Retrospective Studies ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors
Czasopismo naukowe
Tytuł :
Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease.
Autorzy :
Dolovich C; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Bernstein CN; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.
Singh H; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.
Nugent Z; University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada; CancerCare Manitoba, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Tennakoon A; University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.
Shafer LA; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Marrie RA; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Sareen J; Department of Psychiatry, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Targownik LE; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Division of Gastroenterology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: .
Pokaż więcej
Źródło :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2021 Jun; Vol. 19 (6), pp. 1200-1208.e1. Date of Electronic Publication: 2020 Jul 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Inflammatory Bowel Diseases*/complications
Inflammatory Bowel Diseases*/drug therapy
Tumor Necrosis Factor Inhibitors*
Adalimumab ; Anxiety ; Depression/drug therapy ; Humans ; Infliximab ; Quality of Life ; Retrospective Studies ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Tytuł :
Multiple pustular lesions in a patient with ulcerative colitis - successfully treated with TNF-alpha-inhibitor.
Autorzy :
Boehmer DF; Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
Möckel S; Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
Eyerich K; Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
Biedermann T; Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
Posch C; Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
Pokaż więcej
Źródło :
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG [J Dtsch Dermatol Ges] 2021 May; Vol. 19 (5), pp. 782-784. Date of Electronic Publication: 2020 Sep 28.
Typ publikacji :
Case Reports
MeSH Terms :
Colitis, Ulcerative*/diagnosis
Colitis, Ulcerative*/drug therapy
Tumor Necrosis Factor-alpha*
Humans ; Tumor Necrosis Factor Inhibitors
Raport
Tytuł :
Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-α antagonist immunogenicity - does location matter?
Autorzy :
Wilson A; Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.; Division of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.; Department of Physiology & Pharmacology, Western University, London, ON, Canada.
Kim RB; Division of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.; Department of Physiology & Pharmacology, Western University, London, ON, Canada.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 May; Vol. 53 (9), pp. 1055-1056.
Typ publikacji :
Letter; Comment
MeSH Terms :
Inflammatory Bowel Diseases*
Tumor Necrosis Factor-alpha*/genetics
Alleles ; Antibody Formation ; Genetic Variation ; Genotype ; HLA-DQ alpha-Chains/genetics ; Humans ; Infliximab ; Tumor Necrosis Factor Inhibitors
Opinia redakcyjna
Tytuł :
TNFα and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer?
Autorzy :
Benoot T; Laboratory for Molecular and Cellular Therapy, Department Biomedical Science, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium.
Piccioni E; Laboratory for Molecular and Cellular Therapy, Department Biomedical Science, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium.
De Ridder K; Laboratory for Molecular and Cellular Therapy, Department Biomedical Science, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium.
Goyvaerts C; Laboratory for Molecular and Cellular Therapy, Department Biomedical Science, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 13; Vol. 22 (16). Date of Electronic Publication: 2021 Aug 13.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Down-Regulation*
Immune Checkpoint Inhibitors/*therapeutic use
Lung Neoplasms/*genetics
Tumor Necrosis Factor-alpha/*genetics
ADAM17 Protein/genetics ; Cell Survival ; Gene Expression Regulation, Neoplastic ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Receptors, Tumor Necrosis Factor, Type I/genetics ; Receptors, Tumor Necrosis Factor, Type I/metabolism ; Receptors, Tumor Necrosis Factor, Type II/genetics ; Receptors, Tumor Necrosis Factor, Type II/metabolism ; Signal Transduction/drug effects ; Tumor Necrosis Factor-alpha/metabolism
Czasopismo naukowe
Tytuł :
Effects of selective TNFR1 inhibition or TNFR2 stimulation, compared to non-selective TNF inhibition, on (neuro)inflammation and behavior after myocardial infarction in male mice.
Autorzy :
Gouweleeuw L; Department of Neurobiology, GELIFES, University of Groningen, the Netherlands.
Wajant H; Department of Internal Medicine II, Division of Molecular Internal Medicine, University Hospital Wurzburg, Germany.
Maier O; Institute of Cell Biology and Immunology, University of Stuttgart, Germany.
Eisel ULM; Department of Neurobiology, GELIFES, University of Groningen, the Netherlands.
Blankesteijn WM; Department of Pharmacology & Toxicology, CARIM, University of Maastricht, the Netherlands.
Schoemaker RG; Department of Neurobiology, GELIFES, University of Groningen, the Netherlands; Department of Cardiology, University Medical Center Groningen, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Brain, behavior, and immunity [Brain Behav Immun] 2021 Mar; Vol. 93, pp. 156-171. Date of Electronic Publication: 2021 Jan 12.
Typ publikacji :
Journal Article
MeSH Terms :
Myocardial Infarction*/complications
Receptors, Tumor Necrosis Factor, Type I*
Animals ; Inflammation ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Receptors, Tumor Necrosis Factor, Type II ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Tytuł :
Modulating inflammation through the neutralization of Interleukin-6 and tumor necrosis factor-α by biofunctionalized nanoparticles.
Autorzy :
Lima AC; 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Amorim D; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
Laranjeira I; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
Almeida A; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
Reis RL; 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Ferreira H; 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Pinto-Ribeiro F; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
Neves NM; 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal. Electronic address: .
Pokaż więcej
Źródło :
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2021 Mar 10; Vol. 331, pp. 491-502. Date of Electronic Publication: 2021 Feb 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Nanoparticles*
Tumor Necrosis Factor-alpha*
Humans ; Inflammation/drug therapy ; Interleukin-6 ; Tumor Necrosis Factor Inhibitors
Czasopismo naukowe
Tytuł :
Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease.
Autorzy :
Hong SW; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Park J; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Yoon H; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Yang HR; Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea.
Shin CM; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Park YS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Kim N; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Lee DH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Kim JS; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło :
The Korean journal of internal medicine [Korean J Intern Med] 2021 Mar; Vol. 36 (Suppl 1), pp. S9-S17. Date of Electronic Publication: 2020 Jun 25.
Typ publikacji :
Journal Article
MeSH Terms :
Inflammatory Bowel Diseases*/drug therapy
Tumor Necrosis Factor Inhibitors*
Adalimumab ; Female ; Humans ; Immunologic Factors/adverse effects ; Infliximab ; Retrospective Studies ; Seoul ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Tytuł :
Antidrug antibodies to tumour necrosis factor inhibitors in hidradenitis suppurativa: a systematic review.
Autorzy :
Lu JD; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Milakovic M; Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Piguet V; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.; Division of Dermatology, Women's College Hospital, Toronto, ON, Canada.
Alavi A; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.; Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło :
The British journal of dermatology [Br J Dermatol] 2021 Mar; Vol. 184 (3), pp. 555-557. Date of Electronic Publication: 2021 Feb 08.
Typ publikacji :
Letter; Systematic Review
MeSH Terms :
Hidradenitis Suppurativa*/drug therapy
Tumor Necrosis Factor Inhibitors*
Antibodies ; Humans ; Tumor Necrosis Factor-alpha
Opinia redakcyjna
Tytuł :
Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
Autorzy :
Nigam GB; Specialist Registrar Gastroenterology.
Bhandare AP; Speciality Doctor Gastroenterology, The Pennine Acute Hospitals NHS Trust.
Antoniou GA; Consultant Vascular & Endovascular Surgeon, The Pennine Acute Hospitals NHS Trust, Manchester Academic Health Sciences.
Limdi JK; Head-Inflammatory Bowel Diseases Section, The Pennine Acute Hospitals NHS Trust, MAHSC Hon Clinical Professor-Manchester Academic Health Sciences, University of Manchester, Manchester, UK.
Pokaż więcej
Źródło :
European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2021 Mar 01; Vol. 33 (3), pp. 346-357.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Inflammatory Bowel Diseases*/drug therapy
Inflammatory Bowel Diseases*/epidemiology
Tumor Necrosis Factor Inhibitors*
Adalimumab ; Female ; Humans ; Infliximab/adverse effects ; Male ; Retrospective Studies ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Tytuł :
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
Autorzy :
Faleck DM; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Gastroenterology, Hepatology and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: .
Shmidt E; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota.
Huang R; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.
Katta LG; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.
Narula N; Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Pinotti R; Levy Library, Icahn School of Medicine at Mount Sinai, New York, New York.
Suarez-Farinas M; Department of Population Health Science and Policy, Department of Genetics and Genomics Science, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York.
Colombel JF; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Pokaż więcej
Źródło :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2021 Feb; Vol. 19 (2), pp. 238-245.e4. Date of Electronic Publication: 2020 Jun 20.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Crohn Disease*/drug therapy
Tumor Necrosis Factor Inhibitors*
Humans ; Infliximab ; Remission Induction ; Steroids ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Tytuł :
Current Perspectives on the Role of TNF in Hematopoiesis Using Mice With Humanization of TNF/LT System.
Autorzy :
Gogoleva VS; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.; Department of Immunobiology and Biomedicine, Sirius University of Science and Technology, Sirius, Russia.
Atretkhany KN; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
Dygay AP; Department of Immunobiology and Biomedicine, Sirius University of Science and Technology, Sirius, Russia.; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.; Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
Yurakova TR; Department of Immunobiology and Biomedicine, Sirius University of Science and Technology, Sirius, Russia.; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.; Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
Drutskaya MS; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.; Department of Immunobiology and Biomedicine, Sirius University of Science and Technology, Sirius, Russia.
Nedospasov SA; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.; Department of Immunobiology and Biomedicine, Sirius University of Science and Technology, Sirius, Russia.; Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 May 13; Vol. 12, pp. 661900. Date of Electronic Publication: 2021 May 13 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoiesis/*drug effects
Hematopoiesis/*immunology
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Tumor Necrosis Factor-alpha/*immunology
Animals ; Cells, Cultured ; Humans ; Inflammation/immunology ; Mice ; Mice, Transgenic ; Receptors, Tumor Necrosis Factor, Type I/antagonists & inhibitors ; Receptors, Tumor Necrosis Factor, Type II/antagonists & inhibitors ; Signal Transduction
Czasopismo naukowe
Tytuł :
Overexpression of TNFα induces senescence, autophagy and mitochondrial dysfunctions in melanoma cells.
Autorzy :
Tyciakova S; Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. .
Valova V; Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia.; Department of Genetics, Faculty of Natural Sciences, Comenius University, Mlynská dolina, Ilkovicova 6, 842 15, Bratislava, Slovakia.
Svitkova B; Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia.
Matuskova M; Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia.
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 May 06; Vol. 21 (1), pp. 507. Date of Electronic Publication: 2021 May 06.
Typ publikacji :
Journal Article
MeSH Terms :
Autophagy/*physiology
Melanoma/*pathology
Mitochondria/*physiology
Tumor Necrosis Factor-alpha/*physiology
Aldehyde Dehydrogenase/metabolism ; Cell Line, Tumor ; Cellular Senescence ; Colorectal Neoplasms/pathology ; Humans ; Interleukin-6/genetics ; Receptors, Tumor Necrosis Factor, Type I/physiology ; Receptors, Tumor Necrosis Factor, Type II/physiology ; TNF-Related Apoptosis-Inducing Ligand/genetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies